ArticleCureus2025
Clinical and Histopathological Correlations With Blood Groups in Patients With Gastric Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Gastric cancer results from intricate gene-environment interactions, and defining both modifiable and inherited risk factors could improve prevention and personalised therapy. Although ABO blood groups have been linked to gastric cancer susceptibility, findings are inconsistent. Materials and methods We retrospectively compared 214 histologically confirmed gastric cancer cases with 214 age- and sex-matched healthy controls. Presenting symptoms, physical findings (palpable mass, jaundice, ascites, hepatomegaly) and upper-gastrointestinal bleeding were recorded. Endoscopy documented tumour location (cardia, corpus, antrum, incisura angularis, whole stomach) and Borrmann type. Biopsies were classified as adenocarcinoma, signet-ring cell carcinoma, neuroendocrine tumour or lymphoma. ABO blood group was determined serologically, and tumour-node-metastasis (TNM) stage assigned by imaging. Results The cancer cohort comprised 149 men and 65 women and the control group 107 men and 107 women. ABO distributions were as follows: A, 50.5 %; B, 16.8 %; AB, 2.8% and O, 29.9 % in cases, versus 43.0%, 16.4%, 8.0% and 32.6% in controls, respectively. Blood group A showed a non-significant excess risk, whereas AB showed a non-significant deficit (p>0.05). Epigastric pain occurred significantly more often in AB and O groups than in A and B groups (p<0.05). No other clinical, endoscopic, histological or staging variables differed by blood group. Conclusions Our findings suggest a potential increase in gastric cancer risk associated with blood group A, and a possible protective effect of group AB, although statistical significance was not achieved. These observations underscore the need for larger, multicentre prospective studies incorporating genetic and environmental factors to clarify the mechanistic role of ABO antigens in gastric carcinogenesis and to improve risk stratification and early detection strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.